Hey, university friends… Breathe.

The recent slashing of NIH indirect cost rates is unlikely to survive. It’s another Trump stunt.

Courts will have a say. And so will OMB.

And pharmaceutical companies won’t stand for it. NIH-backed research enjoys a ton of congressional (and lobbyist) support.

Comments